Search Results

You are looking at 1 - 10 of 237 items for :

  • "neoadjuvant chemotherapy" x
  • User-accessible content x
Clear All
Full access

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy and Aditya Bardia

young women with breast cancer. Neoadjuvant chemotherapy (NAC) is being increasingly used in the management of localized breast cancer as an alternative to adjuvant chemotherapy. Studies have shown that the benefit of chemotherapy is similar when given

Full access

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma and Imran Zoberi

advanced TNBC typically receive chemotherapy, surgery, and radiation therapy (RT). More recently, the concept of neoadjuvant chemotherapy (NAC) followed by surgery and RT has been introduced in women with locally advanced or palpable TNBC, 6 because TNBC

Full access

William R. Kennedy, Christopher Tricarico, Prashant Gabani, Ashley A. Weiner, Michael B. Altman, Laura L. Ochoa, Maria A. Thomas, Julie A. Margenthaler, Souzan Sanati, Lindsay L. Peterson, Cynthia X. Ma, Foluso O. Ademuyiwa and Imran Zoberi

, management has changed little because TNBC is typically still treated as a single disease entity. With the increasing use of neoadjuvant chemotherapy (NAC), one factor that has emerged as an indicator of responsiveness to standard therapy has been the

Full access

Jeffrey Allen and Mohammad Jahanzeb

Edited by Kerrin G. Robinson

lung cancer (NSCLC): follow-up on a phase III trial [abstract] . J Clin Oncol 2007 ; 25 ( Suppl 1 ): 7520 . 30. Sorensen JB Riska H Ravn J . Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3 [abstract

Full access

Holly Dushkin and Massimo Cristofanilli

version of these guidelines, visit the NCCN Web site at www.NCCN.org ) list the standard approach to treating IBC as neoadjuvant chemotherapy with an anthracycline-based regimen and a taxane. If HER2 is overexpressed, trastuzumab for a total of 1 year is

Full access

Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber and Anusha Kalbasi

neoadjuvant chemotherapy use in the setting of equivocal evidence for the treatment of adult patients with primary high-grade STS. Furthermore, we sought to characterize the factors associated with the use of each of these treatment regimens at Commission on

Full access

Venkata Pokuri, Norbert Sule, Yousef Soofi, Bo Xu, Khurshid Guru and Saby George

-based neoadjuvant chemotherapy has been shown to improve survival in patients with localized muscle-invasive bladder cancer. 2 - 5 In the metastatic setting, gemcitabine/cisplatin (GC) showed similar efficacy to MVAC (methotrexate

Full access

Matthew D. Galsky, Harry W. Herr and Dean F. Bajorin

study . J Urol 1995 ; 153 : 964 – 973 . 15 Shipley WU Winter KA Kaufman DS . Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and

Full access

Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli and Kathleen C. Horst

-positive and triple-negative breast cancer (TNBC) in this group, these women are also more likely to have pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC), 7 – 9 which has been extensively studied as a surrogate marker for

Full access

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia and Gary H. Lyman

relative to standard chemotherapy regimens among 16,233 patients with 6 tumor types who were treated with adjuvant or neoadjuvant chemotherapy regimens currently in widespread use in community oncology practices in the United States. Methods Data